Anton J M Loonen

List of Publications by Year in descending order

83 papers	1,362 citations	361045 20 h-index	433756 31 g-index
89 all docs	89 docs citations	89 times ranked	1260 citing authors

#	Article	IF	Citations
1	New insights into the mechanism of drug-induced dyskinesia. CNS Spectrums, 2013, 18, 15-20.	0.7	88
2	The role of the habenula in the transition from reward to misery in substance use and mood disorders. Neuroscience and Biobehavioral Reviews, 2017, 80, 276-285.	2.9	71
3	Circuits regulating pleasure and happiness: the evolution of reward-seeking and misery-fleeing behavioral mechanisms in vertebrates. Frontiers in Neuroscience, 2015, 9, 394.	1.4	68
4	Circuits regulating pleasure and happiness in major depression. Medical Hypotheses, 2016, 87, 14-21.	0.8	56
5	Circuits Regulating Pleasure and Happinessâ€"Mechanisms of Depression. Frontiers in Human Neuroscience, 2016, 10, 571.	1.0	55
6	Tardive dyskinesia and DRD3, HTR2A and HTR2C gene polymorphisms in Russian psychiatric inpatients from Siberia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2009, 33, 475-481.	2.5	53
7	The Mechanism of Drug-induced Akathisia. CNS Spectrums, 2011, 16, 7-10.	0.7	36
8	Improvement of care for the physical health of patients with severe mental illness: a qualitative study assessing the view of patients and families. BMC Health Services Research, 2013, 13, 426.	0.9	36
9	The Schedule for the Assessment of Drug-Induced Movement Disorders (SADIMoD): testâ€"retest reliability and concurrent validity. International Journal of Neuropsychopharmacology, 2000, 3, 285-296.	1.0	34
10	Measuring Movement Disorders in Antipsychotic Drug Trials. Journal of Clinical Psychopharmacology, 2007, 27, 423-430.	0.7	34
11	Circuits regulating pleasure and happiness: evolution and role in mental disorders. Acta Neuropsychiatrica, 2018, 30, 29-42.	1.0	34
12	Apolipoprotein serum levels related to metabolic syndrome in patients with schizophrenia. Heliyon, 2019, 5, e02033.	1.4	34
13	Circuits Regulating Pleasure and Happiness: The Evolution of the Amygdalar-Hippocampal-Habenular Connectivity in Vertebrates. Frontiers in Neuroscience, 2016, 10, 539.	1.4	31
14	Identification of 5-hydroxytryptamine receptor gene polymorphisms modulating hyperprolactinaemia in antipsychotic drug-treated patients with schizophrenia. World Journal of Biological Psychiatry, 2017, 18, 239-246.	1.3	28
15	Neurobiological mechanisms associated with antipsychotic drug-induced dystonia. Journal of Psychopharmacology, 2021, 35, 3-14.	2.0	28
16	Association Between BDNF Gene Variant Rs6265 and the Severity of Depression in Antidepressant Treatment-Free Depressed Patients. Frontiers in Psychiatry, 2020, 11, 38.	1.3	27
17	Dried Blood Spot Analysis for Therapeutic Drug Monitoring of Clozapine. Journal of Clinical Psychiatry, 2017, 78, e1211-e1218.	1.1	25
18	Prolactin gene polymorphism (â˜' 1149 G/T) is associated with hyperprolactinemia in patients with schizophrenia treated with antipsychotics. Schizophrenia Research, 2017, 182, 110-114.	1.1	24

#	Article	IF	Citations
19	Association Study Indicates a Protective Role of Phosphatidylinositol-4-Phosphate-5-Kinase against Tardive Dyskinesia. International Journal of Neuropsychopharmacology, 2015, 18, pyu098-pyu098.	1.0	23
20	Skin disorders in chronic psychiatric illness. Journal of the European Academy of Dermatology and Venereology, 2010, 24, 1151-1156.	1.3	22
21	Cytochrome P450 1A2 co-determines neuroleptic load and may diminish tardive dyskinesia by increased inducibility. World Journal of Biological Psychiatry, 2015, 16, 200-205.	1.3	22
22	Circuits Regulating Pleasure and Happiness in Bipolar Disorder. Frontiers in Neural Circuits, 2017, 11, 35.	1.4	21
23	Evolution of circuits regulating pleasure and happiness with the habenula in control. CNS Spectrums, 2019, 24, 233-238.	0.7	19
24	Adipocytokines and Metabolic Syndrome in Patients with Schizophrenia. Metabolites, 2020, 10, 410.	1.3	19
25	Gaps in health care for the somatic health of outpatients with severe mental illness. International Journal of Mental Health Nursing, 2013, 22, 249-255.	2.1	18
26	Changes in Body Fat and Related Biochemical Parameters Associated With Atypical Antipsychotic Drug Treatment in Schizophrenia Patients With or Without Metabolic Syndrome. Frontiers in Psychiatry, 2019, 10, 803.	1.3	18
27	Putative role of pharmacogenetics to elucidate the mechanism of tardive dyskinesia in schizophrenia. Pharmacogenomics, 2019, 20, 1199-1223.	0.6	17
28	A pharmacogenetic study of patients with schizophrenia from West Siberia gets insight into dopaminergic mechanisms of antipsychotic-induced hyperprolactinemia. BMC Medical Genetics, 2019, 20, 47.	2.1	17
29	Serum BDNFâ€™s Role as a Biomarker for Motor Training in the Context of AR-Based Rehabilitation after Ischemic Stroke. Brain Sciences, 2020, 10, 623.	1.1	17
30	Exploring Brain Derived Neurotrophic Factor and Cell Adhesion Molecules as Biomarkers for the Transdiagnostic Symptom Anhedonia in Alcohol Use Disorder and Comorbid Depression. Frontiers in Psychiatry, 2020, 11, 296.	1.3	17
31	Study of Early Onset Schizophrenia: Associations of GRIN2A and GRIN2B Polymorphisms. Life, 2021, 11, 997.	1.1	17
32	Retrospective evaluation of the effect of omeprazole on clozapine metabolism. International Journal of Clinical Pharmacy, 2004, 26, 180-182.	1.4	16
33	Limited Associations Between 5-HT Receptor Gene Polymorphisms and Treatment Response in Antidepressant Treatment-Free Patients With Depression. Frontiers in Pharmacology, 2019, 10, 1462.	1.6	15
34	Cytokine Level Changes in Schizophrenia Patients with and without Metabolic Syndrome Treated with Atypical Antipsychotics. Pharmaceuticals, 2021, 14, 446.	1.7	15
35	Likelihood of mechanistic roles for dopaminergic, serotonergic and glutamatergic receptors in tardive dyskinesia: A comparison of genetic variants in two independent patient populations. SAGE Open Medicine, 2016, 4, 205031211664367.	0.7	14
36	The evolutionary old forebrain as site of action to develop new psychotropic drugs. Journal of Psychopharmacology, 2018, 32, 1277-1285.	2.0	14

#	Article	IF	Citations
37	Association of Polymorphisms of Serotonin Transporter (5HTTLPR) and 5-HT2C Receptor Genes with Criminal Behavior in Russian Criminal Offenders. Neuropsychobiology, 2017, 75, 200-210.	0.9	13
38	The functional variant rs334558 of GSK3B is associated with remission in patients with depressive disorders. Pharmacogenomics and Personalized Medicine, 2018, Volume 11, 121-126.	0.4	13
39	Pharmacogenetics of tardive dyskinesia in schizophrenia: The role ofCHRM1andCHRM2muscarinic receptors. World Journal of Biological Psychiatry, 2020, 21, 72-77.	1.3	13
40	Association between 8 Pâ€glycoprotein (MDR1/ABCB1) gene polymorphisms and antipsychotic drugâ€induced hyperprolactinaemia. British Journal of Clinical Pharmacology, 2020, 86, 1827-1835.	1.1	13
41	Cortisol and DHEAS Related to Metabolic Syndrome in Patients with Schizophrenia . Neuropsychiatric Disease and Treatment, 2020, Volume 16, 1051-1058.	1.0	12
42	Functional psychopharmacology is the way to go in pharmacotherapy for psychiatric disorders. Acta Psychiatrica Scandinavica, 2010, 122, 435-437.	2.2	11
43	No involvement of the adenosine A2A receptor in tardive dyskinesia in Russian psychiatric inpatients from Siberia. Human Psychopharmacology, 2012, 27, 334-337.	0.7	11
44	Investigating the potential role of BDNF and PRL genotypes on antidepressant response in depression patients: A prospective inception cohort study in treatment-free patients. Journal of Affective Disorders, 2019, 259, 432-439.	2.0	11
45	Genetic Polymorphisms of 5-HT Receptors and Antipsychotic-Induced Metabolic Dysfunction in Patients with Schizophrenia. Journal of Personalized Medicine, 2021, 11, 181.	1.1	11
46	Polymorphisms of Catechol-O-Methyl Transferase (COMT) Gene in Vulnerability to Levodopa-Induced Dyskinesia. Journal of Pharmacy and Pharmaceutical Sciences, 2018, 21, 340-346.	0.9	10
47	Substantial skin disorders in psychiatric illness coincide with diabetes and addiction. Journal of the European Academy of Dermatology and Venereology, 2011, 25, 392-397.	1.3	9
48	Dehydroepiandrosterone sulphate as a putative protective factor against tardive dyskinesia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2014, 50, 172-177.	2.5	9
49	Levodopa-Induced Dyskinesia Is Related to Indirect Pathway Medium Spiny Neuron Excitotoxicity: A Hypothesis Based on an Unexpected Finding. Parkinson's Disease, 2016, 2016, 1-5.	0.6	9
50	5-Hydroxytryptamine Receptors and Tardive Dyskinesia in Schizophrenia. Frontiers in Molecular Neuroscience, 2020, 13, 63.	1.4	9
51	Commentary on â€œA non-reward attractor theory of depressionâ€: A proposal to include the habenula connection. Neuroscience and Biobehavioral Reviews, 2017, 83, 736-741.	2.9	8
52	Body Fat Parameters, Glucose and Lipid Profiles, and Thyroid Hormone Levels in Schizophrenia Patients with or without Metabolic Syndrome. Diagnostics, 2020, 10, 683.	1.3	8
53	Circuits Regulating Pleasure and Happiness - Focus on Potential Biomarkers for Circuitry including the Habenuloid Complex. Acta Neuropsychiatrica, 2022, , 1-36.	1.0	8
54	Association of Cholinergic Muscarinic M4 Receptor Gene Polymorphism with Schizophrenia . The Application of Clinical Genetics, 2020, Volume 13, 97-105.	1.4	7

#	Article	IF	Citations
55	Comparative Characteristics of the Metabolic Syndrome Prevalence in Patients With Schizophrenia in Three Western Siberia Psychiatric Hospitals. Frontiers in Psychiatry, 2021, 12, 661174.	1.3	7
56	Search for Possible Associations of FTO Gene Polymorphic Variants with Metabolic Syndrome, Obesity and Body Mass Index in Schizophrenia Patients. Pharmacogenomics and Personalized Medicine, 2021, Volume 14, 1123-1131.	0.4	7
57	Circuits Regulating Pleasure and Happiness: A Focus on Addiction, Beyond the Ventral Striatum. , 0, , .		6
58	Beta-Endorphin and Oxytocin in Patients with Alcohol Use Disorder and Comorbid Depression. Journal of Clinical Medicine, 2021, 10, 5696.	1.0	6
59	No evidence so far of a major role of AKT1 and GSK3B in the pathogenesis of antipsychoticâ€induced tardive dyskinesia. Human Psychopharmacology, 2019, 34, e2685.	0.7	5
60	Clinical Evaluation of Different Treatment Strategies for Motor Recovery in Poststroke Rehabilitation during the First 90 Days. Journal of Clinical Medicine, 2021, 10, 3718.	1.0	5
61	Influence of eight ABCB1 polymorphisms on antidepressant response in a prospective cohort of treatmentâ€free Russian patients with moderate or severe depression: An explorative psychopharmacological study with naturalistic design. Human Psychopharmacology, 2021, , e2826.	0.7	5
62	Circuits Regulating Pleasure and Happiness in Schizophrenia: The Neurobiological Mechanism of Delusions. , 2016, , .		4
63	Remaining Need for In Vitro Test to Elucidate 5-Hydroxytryptamine 2C Receptor Functioning. Journal of Clinical Psychopharmacology, 2018, 38, 410-411.	0.7	4
64	Consider Role of Glutamatergic Habenula-projecting Globus Pallidus in OCD. Pharmacopsychiatry, 2019, 52, 203-204.	1.7	4
65	Genetic polymorphisms of PIP5K2A and course of schizophrenia. BMC Medical Genetics, 2020, 21, 171.	2.1	4
66	Association of ANKK1 polymorphism with antipsychoticâ€induced hyperprolactinemia. Human Psychopharmacology, 2020, 35, e2737.	0.7	4
67	Preliminary Pharmacogenetic Study to Explore Putative Dopaminergic Mechanisms of Antidepressant Action. Journal of Personalized Medicine, 2021, 11, 731.	1.1	4
68	Association of PIP4K2A Polymorphisms with Alcohol Use Disorder. Genes, 2021, 12, 1642.	1.0	4
69	Putative role of vitamin D in the mechanism of alcoholism and other addictions â€“ a hypothesis. Acta Neuropsychiatrica, 2021, 33, 1-8.	1.0	3
70	Is Somatic Health Screening in Patients With Severe Mental Illness of Added Value?. Perspectives in Psychiatric Care, 2014, 50, 186-192.	0.9	2
71	A New Paradigm to Indicate Antidepressant Treatments. Pharmaceuticals, 2021, 14, 1288.	1.7	2
72	Gene Polymorphisms of Hormonal Regulators of Metabolism in Patients with Schizophrenia with Metabolic Syndrome. Genes, 2022, 13, 844.	1.0	2

#	Article	IF	Citations
73	Cytokine level in patients with mood disorder, alcohol use disorder and their comorbidity. World Journal of Biological Psychiatry, 2023, 24, 243-253.	1.3	2
74	No news without new scientific ideas. CNS Spectrums, 2014, 19, 110-111.	0.7	1
75	Biomarkers of depressive disorders: A multiplex analysis of blood serum. European Psychiatry, 2017, 41, S524-S524.	0.1	1
76	Genes of the Glutamatergic System and Tardive Dyskinesia in Patients with Schizophrenia. Diagnostics, 2022, 12, 1521.	1.3	1
77	Gene polymorphism of dopaminergic, serotoninergic and glutamatergic receptors and tardive dyskinesia in schizophrenia. European Neuropsychopharmacology, 2016, 26, S495-S496.	0.3	0
78	Predictive genetic model for levodopa-induced dyskinesia in patients with Parkinsonâ€™s disease. European Neuropsychopharmacology, 2017, 27, S1039-S1040.	0.3	0
79	Tardive dyskinesia in schizophrenia: Gene polymorphisms of muscarinic and adrenergic receptors. European Neuropsychopharmacology, 2019, 29, S117-S118.	0.3	0
80	P.583 Polymorphisms in BDNF, AKT1, GSK3B genes: possible association with antipsychotic-induced hyperprolactinemia in schizophrenia patients. European Neuropsychopharmacology, 2020, 40, S331-S332.	0.3	0
81	COMT gene polymorphism and antipsychotic- induced hyperprolactinemia in schizophrenia patients. , 2020, , .		0
82	P.0579 Pharmacogenetic study to elucidate putative dopaminergic mechanisms of antidepressant action. European Neuropsychopharmacology, 2021, 53, S424-S425.	0.3	0
83	Population pharmacokinetic model and limited sampling strategy for clozapine using plasma and dried blood spot samples. Therapeutic Advances in Psychopharmacology, 2022, 12, 204512532110658.	1.2	0